These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 10389916)
1. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Morse MA; Deng Y; Coleman D; Hull S; Kitrell-Fisher E; Nair S; Schlom J; Ryback ME; Lyerly HK Clin Cancer Res; 1999 Jun; 5(6):1331-8. PubMed ID: 10389916 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829 [TBL] [Abstract][Full Text] [Related]
3. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells. Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970 [TBL] [Abstract][Full Text] [Related]
4. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients. Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516 [TBL] [Abstract][Full Text] [Related]
5. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
8. Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells. Yamaguchi Y; Ohta K; Kawabuchi Y; Ohshita A; Okita R; Okawaki M; Hironaka K; Matsuura K; Toge T Anticancer Res; 2005; 25(3c):2407-15. PubMed ID: 16080467 [TBL] [Abstract][Full Text] [Related]
9. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y Clin Cancer Res; 2002 Nov; 8(11):3394-400. PubMed ID: 12429626 [TBL] [Abstract][Full Text] [Related]
11. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694 [TBL] [Abstract][Full Text] [Related]
12. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913 [TBL] [Abstract][Full Text] [Related]
14. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494 [TBL] [Abstract][Full Text] [Related]
15. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Nair SK; Hull S; Coleman D; Gilboa E; Lyerly HK; Morse MA Int J Cancer; 1999 Jul; 82(1):121-4. PubMed ID: 10360830 [TBL] [Abstract][Full Text] [Related]
16. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide. Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491 [TBL] [Abstract][Full Text] [Related]
17. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414 [TBL] [Abstract][Full Text] [Related]
18. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Butterfield LH; Ribas A; Dissette VB; Lee Y; Yang JQ; De la Rocha P; Duran SD; Hernandez J; Seja E; Potter DM; McBride WH; Finn R; Glaspy JA; Economou JS Clin Cancer Res; 2006 May; 12(9):2817-25. PubMed ID: 16675576 [TBL] [Abstract][Full Text] [Related]
19. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. Shilyansky J; Jacobs P; Doffek K; Sugg SL J Pediatr Surg; 2007 Jan; 42(1):54-61; discussion 61. PubMed ID: 17208541 [TBL] [Abstract][Full Text] [Related]
20. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Avigan D; Wu Z; Gong J; Joyce R; Levine J; Elias A; Richardson P; Milano J; Kennedy L; Anderson K; Kufe D Clin Cancer Res; 1999 Oct; 5(10):2735-41. PubMed ID: 10537336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]